[fr] Les relations entre poids corporel et anomalies métaboliques ne sont pas univoques. Ainsi, il existe des personnes non obèses métaboliquement anormales (MONW), rarement dépistées en raison d’un poids corporel faussement rassurant, et, à l’inverse, des sujets métaboliquement sains bien qu’ils soient obè ses (MHO). La topographie (intra-abdominale/hépatique vs sous-cutanée périphérique) et l’activité hormono-métabolique et pro-inflammatoire différente des dépôts graisseux semblent jouer un rôle déterminant pour expliquer ce paradoxe. Cet article de revue vise à décrire les grands principes de la prise en charge thérapeutique des personnes MONW, dans le but de réduire le risque accru de diabète de type 2 et de maladies cardiovasculaires, et de discuter les avantages et inconvénients d’une prise en charge classique de l’obésité chez les patients MHO.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Beck, Emmanuel ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Paquot, Nicolas ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Sujets de poids normal «métaboliquement obèses» et sujets obèses «métaboliquement sains»
Publication date :
2009
Journal title :
Revue Médicale de la Suisse Romande
ISSN :
0035-3655
Publisher :
Société Médicale de la Suisse Romande, Lausanne, Switzerland
** Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008;168:1617-1624
Beck N, Scheen AJ. Sujets «métaboliquement obèses» sans excès de poids: un phénotype interpellant. Rev Med Liège 2009;64:14-22.
Beck E, Paquot N, Scheen AJ. Sujets «métaboliquement obèses» de poids normal. 1re partie: Diagnostic Physiopathologie et prévalence. Obésité 2008;3:184-193
* Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699-713.
Beck E, Paquot N, Scheen AJ. Sujets «métaboliquement obèses» de poids normal. 2e partie: Pronostic et prise en charge. Obésité 2008;3:280-285
Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism 2001;50:1499-1504
Esser N, Scheen AJ. Sujets obèses sans anomalies métaboliques. Rev Med Liège 2009;64:148-157
Esser N , Paquot N, Scheen AJ. Sujets «métaboliquement sains», bien qu'obèses. 1re partie: Diagnostic, Physiopathologie et prévalence. Obesité 2009;4:56-65.
Karelis AD. Metabolically healthy but obese individuals. Lancet 2008;372:1281-1283
Esser N , Paquot N, Scheen AJ. Sujets «métaboliquement sains», bien qu'obèses. 2e partie: Pronostic et prise en charge. Obesité 2009;4:134-141
Colombo O, Villani S, Pinelli G, et al. To treat or not to treat: Comparison of different criteria used to determine whether weight loss is to be recommended. Nutr J 2008;7:5. (Pubitemid 351661429)
Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol 2004;29:31-45.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American heart association/National heart, lung, and blood institute scientific statement. Circulation 2005;112:2735-2752
Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish diabetes prevention study. Lancet 2006;368:1673-1679 (Pubitemid 46048554)
Basdevant A, Laville M, Ziegler O. Recommandations pour le diagnostic, la prévention et le traitement des obésités. Diab Metab 1998;24(Suppl. 2):1-48.
Scheen AJ. Diabetes, obesity, and metabolic syndrome. In: Ed: Meckling KA (eds), Nutrient-drug interactions. Boca Raton: CRC Press Taylor & Francis, 2007: 1-30.
Scheen AJ. Nutritional counseling for overweight patients and patients with metabolic syndrome. In: Perk J, Mathes P, Gohlke H, et al (eds). Cardiovascular prevention and rehabilitation. London; Springer-Verlag, 2007:201-211
Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 2008;87:801-809 (Pubitemid 351549222)
Feldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 2007;32:46-60.
Esposito K, Ciotola M, Giugliano D. Mediterranean diet and the metabolic syndrome. Mol Nutr Food Res 2007;51:1268-1274
Minich DM, Bland JS. Dietary management of the metabolic syndrome beyond macronutrients. Nutr Rev 2008;66:429-444
Scheen AJ, Paquot N. Effets bénéfiques de l'activité physique sur les facteurs de risque cardiovasculaire. Rev Med Liège 2001;56:239-243
Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol Nutr Metab 2007;32:76-88.
Gill JM, Malkova D. Physical activity, fitness and cardiovascular disease risk in adults: Interactions with insulin resistance and obesity. Clin Sci (Lond) 2006;110:409-425
DuBose KD, Eisenmann JC. Donnelly JE. Aerobic fitness attenuates the metabolic syndrome score in normal-weight, at-risk-for-overweight, and overweight children. Pediatrics 2007;120:e1262-8.
Scheen AJ. The future of obesity: New drugs versus lifestyle interventions ? Exp Opin Invest Drugs 2008;17:263-267
Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 2007;335:1194-1199 (Pubitemid 350273303)
Scheen AJ, Paquot N. Pharmacological treatment of obesity, food intake, and reversal of metabolic disorders. Curr Nutr Food Sci 2007;3:123-133 (Pubitemid 46773888)
Fontbonne A, Charles MA, Juhan-Vague I, BIGPRO Study Group. The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care 1994;19:920-926
Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791 (Pubitemid 34655345)
Scheen AJ. Integrated approach to treatment and prevention. In: Pharmacotherapy of obesity. Options and alternatives (Eds: Hofbauer KG, Keller U, Boss O). Boca Raton: CRC Press, 2004:449-463
* Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 2006;8:144-156
* Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008;28:1039-1049
Hayes L, Pearce MS, Unwin NC. Lifecourse predictors of normal metabolic parameters in overweight and obese adults. Int J Obes 2006;30:970-976 (Pubitemid 43801198)
* Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168:1609-1616
Magis D, Jandrain BJ, Scheen AJ. Alcool, sensibilité à l'insuline et diabète sucré. Rev Med Liège 2003;58:501-507
Perseghin G. Is a nutritional therapeutic approach unsuitable for metabolically healthy but obese women ? Diabetologia 2008;51:1567-1569
Shin MJ, Hyun YJ, Kim OY, et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: Low inflammation and LDL oxidation in MHO women. Int J Obes Relat Metab Disord 2006;30:1529-1534
Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R. Metabolically healthy but obese women: Effect of an energy-restricted diet. Diabetologia 2008;51:1752-1754
Lee S, Kuk JL, Katzmarzyk PT, et al. Cardiorespiratory fitness attenuates metabolic risk independent of abdominal subcutaneous and visceral fat in men. Diabetes Care 2005;28:895-901. (Pubitemid 40434492)
Ekelund U, Franks PW, Sharp S, et al. Increase in physical activity energy expenditure is associated with reduced metabolic risk independent of change in fatness and fitness. Diabetes Care 2007;30:2101-2106 (Pubitemid 47219429)
Messier V, Malta FM, Rabasa-Lhoret R, et al. Association of cardiorespiratory fitness with insulin sensitivity in overweight and obese postmenopausal women: A Montreal Ottawa new emerging team study. Metabolism 2008;57:1293-1298
Hamer M. The relative influences of fitness and fatness on inflammatory factors. Prev Med 2007;44:3-11. (Pubitemid 46073084)
Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004;164:1092-1097
Eisenmann JC. Aerobic fitness, fatness and the metabolic syndrome in children and adolescents. Acta Paediatr 2007;96:1723-1729
Sui X, LaMonte MJ, Laditka JN, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. JAMA 2007;298:2507-2516 (Pubitemid 350223537)
